New Study Supports Favorable Sexual Function Profile for Nymox's NX-1207 for Prostate Enlargement
HASBROUCK HEIGHTS, N.J., April 16, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today positive new study findings which have demonstrated that the Company's NX-1207 Phase 3 treatment for benign prostatic hyperplasia (BPH or prostatic enlargement) has no detectable effect on key male structures involved in sexual function.
This study has provided new data which offers further scientific support of highly selective sparing of prostatic nerves after NX-1207 treatment. In addition, over 1000 patients in clinical trials who have received Nymox's NX-1207 have not shown any clinical sexual problems related to the drug. One of the several major problems with other existing prostate treatments is the predictable collateral damage to sexual organs which produces serious problems such as impotence, loss of libido, and retrograde ejaculation.
In other studies, intraprostatic NX-1207 has been shown to have no effects on adjacent key organs such as penis and testis, seminal vesicles, urethra and bladder. Male hormone levels are unaffected by
Surgical and other minimally invasive treatments for benign prostatic hyperplasia (BPH) are non-selective in their effects on the prostate.
The end result is improved urinary function at the undesirable cost of lost sexual function. These treatments are known to cause long-term impairment or loss of sexual function in a significant percentage of treated patients.
Drugs that provide only minor improvement in urination frequently produce sexual problems. For example, 5-alpha-reductase inhibitors
(5ARI) often lead to loss of libido, impotence, or male breast enlargement (gynecomastia). Alpha-blocker drugs frequently cause retrograde ejaculation (ejaculation into the bladder) or impotence.
Full results on the new study will be presented at upcoming medical meetings and in publications.
NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials for BPH and Phase 2 for localized prostate cancer.
The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where a single dose of NX-1207 has been found to produce on average symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs.
Follow-up studies have shown evidence of long lasting benefit with a significant proportion of men who received a single dose reporting maintained improvement in BPH symptoms without other treatments for up to 7 1/2 years.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: Brian Doyle
Nymox Pharmaceutical Corporation
Posted: April 2013